VGXI New Headquarters and Biomanufacturing Facility Grand Opening + Ribbon Cutting

October 12, 2022

VGXI Celebrates Grand Opening + Ribbon Cutting Ceremony of New Headquarters and Biomanufacturing Facility in Conroe, TX

On Friday, October 7, 2022, VGXI celebrated the Grand Opening of the new 120,000-square-foot Headquarters and Biomanufacturing Facility with a ribbon cutting ceremony. In attendance for the celebration were Young Park, Chief Executive Officer, VGXI; Dorothy Peterson, Chief Operating Officer, VGXI; The Honorable Myung Soo Ahn, Consul General of the Republic of Korea; U.S. Congressman Kevin Brady (Texas’ 8th District); Danielle Scheiner, Executive Director for Conroe Economic Development; several guests from GeneOne Life Science, Inc. (Parent company to VGXI); and the BE&K Building Group (BE&K) project team.

The new VGXI headquarters features four distinct manufacturing trains with state-of-the-art production equipment, flexible fermentation capacity in excess of 3000L, and expanded GMP fill/finish capabilities. Dedicated areas are also available for mRNA manufacturing and small-scale, rapid turnaround services for personalized therapies. This initial phase quintuples VGXI’s current production capacity and provides much needed space for laboratories, purification, filling, packaging, warehousing, and process support. It also provides measurable office and conference space with associated amenities to accommodate VGXI’s recent and future growth.

Qualification activities are fully underway in preparation for GMP production. To ensure a seamless transition and provide additional overflow capacity, VGXI’s existing facility in The Woodlands will remain fully operational.

BE&K is the design-builder of record, in partnership with architectural partner Hanbury and engineering partner Hipp Engineering & Consulting.

The new VGXI headquarters is ready to support our clients as they achieve successful late phase and commercial launch of their products. Combined with our highly skilled and dedicated team, we are confident VGXI will continue to meet the growing industry demand for these next generation medicines.

— Young Park, VGXI, CEO